research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
Search
for
Sort by
Research
720-750 / 1000+ resultsresearch Androgenetic Alopecia Among Hospital Staff: A Study of Prevalence, Types and a Comparison with General Population in a Secondary Hospital in China
Hospital staff have a higher rate of hair loss than the general population.
research Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib
A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Successful Treatment of Pediatric Alopecia Areata with Siddha Therapeutics
Siddha therapeutics successfully treated a 14-year-old's alopecia areata, leading to full hair regrowth without side effects.
research Allergen‐specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient
Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Claims for the cost of care: local authority provision
The claimant sued for negligence after a hair treatment caused harm and distress, and the defendant responded after legal action started.
research Assess the Attitude Towards Mental Illness Among Nurses Working in Selected Tertiary Care Hospital
Most nurses have negative attitudes towards mental illness, highlighting the need for training to improve their views.
research Alopecia areata associated with haloperidol decanoate long-acting injection
Haloperidol decanoate can cause alopecia areata.
research A questionnaire-based survey among Indian dermatologists regarding the management of androgenetic alopecia with nutritional supplements
Nutritional supplements with natural DHT inhibitors are effective for treating androgenetic alopecia.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research 667 Patient satisfaction with a multidisciplinary alopecia areata group medical visit
Patients were very satisfied with the multidisciplinary group visit for alopecia areata.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research Actinic Keratosis: Risk Factors, Clinical, Diagnosis and Therapeutics Aspects. Part I
Actinic keratosis is a sun-induced skin condition that can potentially turn into skin cancer and requires treatment to prevent malignancy.
research JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
JAK inhibitors show promise in treating difficult skin diseases.
research Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States
Current treatments for Alopecia Areata are unsatisfactory and need improvement.
research Alopecia Areata in Latin America: Where are We and Where are We Going?
Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
research A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.
research How to Find Your New Tax Bracket
The document explains how to determine your tax bracket and the effects of income changes on taxes.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Janus kinase inhibitors for the use of alopecia areata: A promising therapeutic of the future
JAK inhibitors show promise as a future treatment for hair loss.
research PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research A CASE-CONTROL STUDY TO ASSESS THE ASSOCIATION OF ALOPECIA AREATA WITH THYROID DYSFUNCTION AND THYROID AUTOIMMUNITY
People with alopecia areata are more likely to have thyroid autoimmunity, but not thyroid disease.